RIP to Glucocorticoids in GPA For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). https://t.co/WqpO6ACqtu https://t.co/vb8qx3uHA0

• RIP to Glucocorticoids in GPA | RheumNow

Wang et al. Propensity score matched cohort study. 63,302 individuals. Colchicine associated lower risk of THR/TKR, HR 0.87. @RheumNow #ACR24 Abstr#2557 https://t.co/UUU3Tm67ML https://t.co/uKi0e8E7HV

• The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a …
• https://x.com/RichardPAConway/status/1858572127508877503/photo/1

Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3

• Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Ope…
• https://x.com/RichardPAConway/status/1858557782405833156/photo/1

In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Phase 2b , placebo control, double blind study Abst #L08 #ACR24 @RheumNow https://t.co/j4qkj1Xvbr

• https://x.com/bella_mehta/status/1858558034366304734/photo/1

#2286🔬Certolizumab Pegol (CZP) in High RF RA 📊Pooled analysis;N=1180 💥PBO: High RF=more radiographic progression v low RF (Wk24 6.5 v 2.8%,Wk52 17.6 v 10.4%) 💥CZP: min. progression regardless of RF (Wk24 0 v 1.1%;Wk52 5.3 v 3.1%) #ACR24 @RheumNow https://t.co/koel7SDsUb

• https://x.com/CaoilfhionnMD/status/1858548471554605138/photo/1

Tesser et al. Implanted cervical vagus nerve stimulator for b/tsDMARD-IR RA. 242 patients. ACR20 week 12 35% vs 24%. Higher rates of DAS28-CRP LDA/remission. @RheumNow #ACR24 Abstr#L10 https://t.co/OXojHEMkKQ https://t.co/XSt97u7LrR

• Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Respo…
• https://x.com/RichardPAConway/status/1858549226499645467/photo/1

Ren et al. XG005, compound with NSAID and neuropathic like effects, in knee OA. At week 4 significant improvements in WOMAC pain, stiffness, function, and primary endpoint of walking pain @RheumNow #ACR24 Abstr#L08 https://t.co/gQDwAmzI4G https://t.co/b22XC7rXnE

• A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Para…
• https://x.com/RichardPAConway/status/1858542683087835421/photo/1

Depressing finding re:glucocorticoid discontinuation in SLE No improvement over decades in rate of GC discontinuation; if anything, we start more GC than ever @AliDuarteMD help me out here; why haven't we made more progress? #ACR24 @RheumNow Abstr#2421 https://t.co/uzZATKPWVC

• https://x.com/EBRheum/status/1858543437903004159/photo/1
• https://x.com/EBRheum/status/1858543437903004159/photo/1
• https://x.com/EBRheum/status/1858543437903004159/photo/1

The updated 2024 ACR Guideline for Dx and Tx of #lupus nephritis is here! Dr. Lisa Samaritano discusses the key recommendations 👇 For all pts: screen for LN, give HCQ and RAAS for pts with ⬆️ proteinuria GCs in pts w/ LN class III/IV &/or V. @Rheumnow #ACR24 @rheumarhyme https://t.co/wLVRGktR59

• https://x.com/RHEUMarampa/status/1858534848090021939/photo/1
• https://x.com/RHEUMarampa/status/1858534848090021939/photo/1

Recommend "Triple Therapy" = Glucocorticoids + two other agents Practically, that means MMF + belimumumab OR CNI for most pts For the CYC afficionados, the lower-dose EUROLUPUS protocol is preferred #ACR24 @RheumNow https://t.co/0gRISXSw0c

• https://x.com/EBRheum/status/1858535181373563219/photo/1